Aim Immunotech Stock Investor Sentiment

AIM Stock  USD 0.22  0.01  3.91%   
About 54% of AIM ImmunoTech's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding AIM ImmunoTech suggests that some traders are interested. AIM ImmunoTech's investing sentiment overview a quick insight into current market opportunities from investing in AIM ImmunoTech. Many technical investors use AIM ImmunoTech stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

AIM ImmunoTech Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards AIM ImmunoTech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at gurufocus.com         
Ai-Media Technologies Ltd Q4 2024 Earnings Call Transcript Highlights Strong Revenue ...
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Full Year 2024 Ai-Media Technologies Ltd Earnings Call Transcript
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Half Year 2024 Ai-Media Technologies Ltd Earnings Call Transcript
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Acquisition by Thomas Equels of 20000 shares of AIM ImmunoTech at 0.308 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over three months ago at simplywall.st         
Top 3 ASX Stocks Estimated To Be Undervalued In September 2024
Simply Wall St News at Macroaxis
over three months ago at businesswire.com         
Advyzon Investment Management Wins WealthManagement.com Industry Award for Model Marketplaces
businesswire News
over three months ago at finance.yahoo.com         
Acquisition by Thomas Equels of 312500 shares of AIM ImmunoTech at 0.32 subject to Rule 16b-3
Yahoo News
over three months ago at finance.yahoo.com         
ASX Value Picks Including Kina Securities And 2 Others With Estimated Discount Pricing
Yahoo News
over three months ago at globenewswire.com         
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Amplige...
Macroaxis News: globenewswire.com
over three months ago at finance.yahoo.com         
AI-Media and ITV Announce Landmark Partnership to Revolutionize Captioning Services
Yahoo News
over three months ago at businesswire.com         
Abu Dhabi ospiter il Congresso AIM 2025, con oltre 25.000 partecipanti provenienti da 180 paesi
businesswire News
over three months ago at finance.yahoo.com         
AI-Media to Showcase Cutting-Edge Alta Platform Innovations at IBC 2024
Yahoo News
over three months ago at businesswire.com         
Abu Dhabi sediar o AIM Congress 2025, contando com mais de 25.000 participantes de 180 pases
businesswire News
over three months ago at businesswire.com         
Abou Dhabi accueillera AIM Congress 2025, runissant plus de 25 000 participants provenant de 180 pay...
businesswire News
over three months ago at businesswire.com         
Abu Dhabi Set to Host AIM Congress 2025, Featuring Over 25,000 Participants From 180 Countries
businesswire News
Far too much social signal, news, headlines, and media speculation about AIM ImmunoTech that are available to investors today. That information is available publicly through AIM media outlets and privately through word of mouth or via AIM internal channels. However, regardless of the origin, that massive amount of AIM data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of AIM ImmunoTech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AIM ImmunoTech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AIM ImmunoTech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AIM ImmunoTech alpha.

AIM ImmunoTech Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Stewart Appelrouth of 568 shares of AIM ImmunoTech at 9.68 subject to Rule 16b-3
10/29/2024
2
Acquisition by Thomas Equels of 377358 shares of AIM ImmunoTech at 0.265 subject to Rule 16b-3
10/30/2024
3
Acquisition by Thomas Equels of 300000 shares of AIM ImmunoTech at 0.47 subject to Rule 16b-3
11/08/2024
4
Kellner Group Urges Stockholders of AIM Immunotech to VoteGold
11/19/2024
5
AIM Menandatangani Perjanjian Penting 5 Tahun dengan Central European Media Enterprises
12/04/2024
6
Blend Positioned in Leaders Quadrant in AIM Researchs Top Generative AI Services Providers 2024 Report
12/09/2024
7
Anthony Abrahams Buys Handful Of Shares In Ai-Media Technologies
12/10/2024
8
AIMs Clinical Strategy Under Incumbent Board Has Totally Failed
12/11/2024
9
Anthony Abrahams Buys 250,000 Shares of Ai-Media Technologies Limited Stock
12/12/2024
10
Acquisition by Bryan Nancy of 24452 shares of AIM ImmunoTech at 0.213 subject to Rule 16b-3
12/13/2024
11
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
12/17/2024
12
Disposition of 4580 shares by William Mitchell of AIM ImmunoTech at 0.193 subject to Rule 16b-3
12/19/2024
13
Ai-Media Technologies Limited Insider Buys A250,312.50 in Stock
12/23/2024
14
Acquisition by William Mitchell of 26305 shares of AIM ImmunoTech at 0.198 subject to Rule 16b-3
12/31/2024
15
Acquisition by Stewart Appelrouth of 1136 shares of AIM ImmunoTech at 16.72 subject to Rule 16b-3
01/08/2025
16
Truv Integrates with Freddie Mac AIM Check API
01/14/2025
17
AIM ImmunoTech Upgraded to Strong Buy What Does It Mean for the Stock
01/17/2025
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
Check out AIM ImmunoTech Hype Analysis, AIM ImmunoTech Correlation and AIM ImmunoTech Performance.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.47)
Revenue Per Share
0.004
Quarterly Revenue Growth
0.19
Return On Assets
(0.80)
Return On Equity
(1.55)
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.